Therapeutic Targeting Of The Human Islet Environment (UC4) | RFA DK 17 003

Opportunity Information: Apply for RFA DK 17 003

The Therapeutic Targeting Of The Human Islet Environment (UC4) funding opportunity (RFA-DK-17-003) is a National Institutes of Health (NIH) cooperative agreement designed to push forward practical, in vivo approaches for protecting, restoring, or expanding functional human beta cell mass, with the larger goal of preventing or treating Type 1 Diabetes (T1D). The core idea is to focus on the human pancreatic and islet environment as it exists inside the body, rather than relying only on isolated cells or purely in vitro systems. Projects are expected to be highly translational and strategy-driven, aimed at overcoming real delivery, targeting, safety, and monitoring barriers that stand between promising beta cell therapies and actual clinical impact.

A major emphasis of the announcement is the development of methods that can precisely target the pancreas or islet microenvironment in vivo to deliver therapeutic payloads. These payloads can include cell-based therapeutics (for example, approaches that introduce or support functional insulin-producing cells), regulatory molecules (such as biologics or other modulators that influence immune attack, inflammation, or beta cell survival), or gene constructs (tools to alter gene expression or cellular behavior in ways that preserve or regenerate beta cells). The intended outcome is either protection of remaining beta cells, replenishment of beta cell mass, or both, in a way that is feasible and safe enough to envision use in humans.

In parallel, the FOA also invites the creation of synthetic sentinel biomarkers that can safely detect beta cell stress or very early disease activity before traditional markers appear. A specific motivation mentioned is identifying beta cell stress or disease initiation prior to the appearance of autoantibodies in people at risk for T1D. In practical terms, this line of work targets a major clinical gap: the ability to monitor the earliest stages of beta cell injury in a minimally invasive and reliable way, potentially enabling earlier intervention and better risk stratification than is possible with current immune markers alone.

Awardees funded through this mechanism become part of the Consortium on Targeting and Regeneration (CTAR), which is organized to accelerate innovative strategies that increase functional human beta cell mass in vivo. CTAR supports approaches grounded in controlled manipulation of beta cell replication, islet cell plasticity, and reprogramming of pancreatic non-beta cells into beta-like cells. That framing matters because it sets expectations that proposed projects should connect to one or more of these regenerative or protective avenues, and that they should be built around controllability, specificity, and safety in the living human pancreatic context. CTAR itself sits within the broader Human Islet Research Network (HIRN), signaling that funded projects are meant to contribute to a coordinated national research effort with shared goals, standards, and collaborative opportunities.

From an administrative and funding structure perspective, this opportunity is categorized as discretionary funding and uses a cooperative agreement (UC4) mechanism. A cooperative agreement typically implies substantial programmatic involvement by NIH staff compared with a standard grant, often including milestone-driven management, coordination across consortium sites, and expectations around data sharing or participation in consortium activities. The activity category is listed under Food and Nutrition, Health, and the CFDA number associated with this opportunity is 93.847.

Eligibility is broad and includes many types of domestic institutions and organizations, reflecting an intent to draw in diverse scientific, engineering, and translational teams. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (outside higher education); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, faith-based or community-based organizations, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, U.S. territories or possessions, eligible federal agencies, and even non-U.S. (foreign) entities and regional organizations. This wide net suggests the program is open to interdisciplinary collaborations spanning academia, biotech, clinical research groups, and organizations with specialized capabilities in delivery systems, biomaterials, imaging, synthetic biology, or translational diagnostics.

Key dates and funding parameters included in the source information indicate the FOA was created on 2016-12-14 with an original closing date of 2017-03-22. The listed award ceiling is $600,000, and the expected number of awards is not specified in the provided data. Overall, the opportunity is positioned as a focused, consortium-based push to solve two tightly linked problems in T1D: how to deliver therapies directly and effectively within the pancreatic islet environment to preserve or regenerate beta cells, and how to monitor beta cell stress early and safely enough to enable intervention before irreversible damage and overt autoimmunity are clearly detectable.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Therapeutic Targeting Of The Human Islet Environment (UC4)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2016-12-14.
• Applicants must submit their applications by 2017-03-22. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $600,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 17 003

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: